A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
Int J Clin Exp Med
Objective: The aim of this study was to indirectly compare the efficacy and safety of anti-tumor necrosis factor α (TNFα) agents and an interleukin (IL)-17A inhibitor Secukinmuab for the treatment of ankylosing spondy-litis (AS). Methods: Literatures were searched in Pubmed, Medline, Embase and the Cochrane library to screen citations from January 1996 to December 2015. The mixed treatment comparison (MTC) meta-analysis within a Bayesian framework was performed by WinBUGS14 software. Thefatcat:4bsbjqeq5jf25mw4znfb45c5p4